Significance of detection of serum β_2-microglobulin in patients with esophageal cancer
YANG Wenfeng WANG Shanzheng YANG Guotao et al. (Hospital,Shandong University, Jinan 250012)
Objective Clinical use of β 2 microglobulin (β 2 MG) in esophageal cancer in diagnosis?treatment and prognosis was evaluated. Methods The serum β 2 MG in 71 patients with esophageal cancer, in 32 patients with esophageal benign disease and in 40 normal persons as a control, was tested with immunoradiometric assay (IRA). Results The average concentration of disease β 2 MG was 1.69±0.51 mg·L -1 in esophageal benign disease group, 2.41±0.56 mg·L -1 in esophageal cancer group, and 1.62±0.17 mg·L -1 in the control. The statistic difference between cancer and benign or control group was P 0.05. The serum β 2 MG lowered down in esophageal cancer group after operation ( P 0.05),and remained higher at the time of metastasis or recurrence. Conclusion The serum β 2 MG level was higher in the patients with esophageal cancer, and was closely related to diagnosis? treatment and prognosis of esophageal cancer.
【CateGory Index】： R735.1